Ascentage Pharma Group International (NASDAQ:AAPG) Announces Earnings Results

Ascentage Pharma Group International (NASDAQ:AAPG) issued its quarterly earnings results on Thursday. The company reported ($0.52) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $24.72 million for the quarter.

Ascentage Pharma Group International Stock Down 3.8%

Ascentage Pharma Group International stock traded down $0.86 during mid-day trading on Thursday, hitting $21.53. The company had a trading volume of 1,408 shares, compared to its average volume of 3,313. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. Ascentage Pharma Group International has a 1 year low of $17.56 and a 1 year high of $48.45. The business has a fifty day moving average of $24.22 and a 200 day moving average of $30.05.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AAPG shares. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. BTIG Research began coverage on shares of Ascentage Pharma Group International in a research note on Thursday, March 12th. They issued a “buy” rating and a $48.00 price target for the company. Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, Oppenheimer initiated coverage on Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and five have issued a Buy rating to the company’s stock. According to data from MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and an average target price of $48.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth $383,000. XY Capital Ltd grew its holdings in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter. UBS Group AG grew its holdings in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International during the third quarter worth about $204,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Ascentage Pharma Group International in the 3rd quarter valued at about $96,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.